Clinical Development Failure Risk: Their lead drug candidates, CRB-701 and CRB-601, are in early stages of clinical development, and there is a high risk that these or other future product candidates will fail to demonstrate safety and efficacy in clinical trials or fail to receive regulatory approval.

Regulatory Approval Uncertainty Risk: Even if clinical trials are successful, obtaining necessary regulatory approvals for their drug candidates is a lengthy, expensive, and uncertain process, and they may not receive approval for any of their product candidates.

Future Funding and Dilution Risk: Corbus Pharmaceuticals will require substantial additional capital to fund its operations and complete the development and potential commercialization of its product candidates, and such capital may not be available on favorable terms or at all, potentially leading to significant shareholder dilution.